Roivant Sciences Ltd. logo ROIV - Roivant Sciences Ltd.

NEXT EARNINGS: Jun 4, 2026 EPS Est: $-0.26
Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 13
HOLD 1
SELL 0
STRONG
SELL
0
| PRICE TARGET: $31.25 DETAILS
HIGH: $33.00
LOW: $30.00
MEDIAN: $31.00
CONSENSUS: $31.25
UPSIDE: 10.58%
Market Cap: 20.23B
Volume: 5,569,401
Avg Volume: 7,165,053
52 Week Range: 8.73-28.29
Sector: Healthcare
Industry: Biotechnology
Beta: 1.23
Last Dividend: $N/A
Exchange: NASDAQ
Country: GB
Employees: 908
IPO Date: 2020-12-08
EPS (TTM): -0.24
P/E Ratio: -42.56
Revenue (TTM): 29.05M
Total Assets: 5.44B
Total Debt: 100.17M
Cash & Equiv: 2.72B
Rev Growth (5Y): -15.6%
EPS Growth (5Y): N/A
FCF Growth (5Y): N/A
ROCE: -21.1%
Debt/Equity: 0.02

Earnings History

Date EPS Actual EPS Est EPS Surprise Rev Actual Rev Est Rev Surprise
2026-02-06 $-0.24 $-0.27 +11.1% $2.0M $4.3M -54.0%
2025-11-10 $-0.28 $-0.32 +12.4% $1.6M $5.6M -72.0%
2025-08-11 $-0.18 $-0.25 +27.9% $2.2M $7.3M -70.3%
2025-05-29 $-0.22 $-0.26 +16.5% $7.6M $54.1M -86.0%
2025-02-10 $-0.13 $-0.24 +45.8% $9.0M $62.2M -85.5%
2024-11-12 $-0.29 $-0.25 -17.4% $4.5M $45.9M -90.3%
2024-08-08 $-0.18 $-0.24 +26.0% $55.1M $30.7M +79.5%
2024-05-30 $-0.23 $-0.26 +13.0% $28.9M $31.0M -6.7%

Track Record

Statements >
Metric 2024 2023 2022 2021 2020 2019
Revenue 29.05M 32.71M 61.28M 55.29M 23.80M 67.69M
Net Income (171.98M) 4.35B (1.01B) (845.26M) (809.23M) 1.20B
EPS -0.24 5.55 -1.42 -1.26 -1.18 1.75
Total Assets 5.44B 7.22B 2.39B 2.59B 2.69B 2.48B
Total Debt 100.17M 499.75M 481.40M 283.89M 244.98M 180.88M
Cash & Equivalents 2.72B 6.54B 1.68B 2.06B 2.13B 2.19B
Operating Cash Flow (839.45M) (765.27M) (843.39M) (677.73M) (552.14M) (761.83M)
Free Cash Flow (844.05M) (766.65M) (856.08M) (695.16M) (557.94M) (766.75M)
FCF per Share -1.16 -0.98 -1.20 -1.04 -0.81 -1.12
Book Value 4.69B 5.97B 1.16B 1.66B 1.90B 2.03B
Cash & ST Investments 4.89B 6.54B 1.68B 2.06B 2.13B 2.19B
ROC Equity -0.04 0.73 -0.87 -0.51 -0.43 0.59